By Hamza Faisal

Big pharma's shopping spree for artificial intelligence just got another headline. Pathos AI, a clinical-stage biotech building drugs with the help of AI, said Friday it has raised $237 million in a Series E round led by Bristol Myers Squibb, valuing the New York-based company at roughly $3 billion. Existing investors joined the round, though the company did not name them.

The raise is a steep step up from Pathos's earlier financings and signals that drugmakers are willing to pay up for AI platforms that can shorten the brutally long and expensive drug-development cycle. Chief executive Iker Huerga framed the company as a system built to, in his words, improve the probability of success in drug development — a bold claim that will ultimately be judged by whether its drugs win approval.

A $3 billion bet on AI-designed drugs

The Series E brings Pathos's total funding to about $704 million. The startup previously raised $365 million in a Series D round at a $1.6 billion post-money valuation in May 2025, after a $62 million Series C at a $600 million valuation in October 2024. Pathos says the fresh money will go toward scaling its AI drug-development platform, Pathos Foundry, and advancing its four clinical-stage cancer programs.

Foundry uses thousands of AI agents to study data about diseases, patients, and clinical trials. The company says that engine let it assemble its current pipeline quickly through a string of deals over the past several months — and that speed is a big part of what investors are paying for.

The pipeline includes JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate that Pathos licensed from China's Alphamab Oncology in August in a deal worth $125 million upfront and up to $2.09 billion in milestone payments. It also includes pocenbrodib, being tested in metastatic castration-resistant prostate cancer and relapsed multiple myeloma; P-100, an ER PROTAC for breast cancer being developed with AstraZeneca; and DO-2, a next-generation MET kinase inhibitor for MET-altered lung cancer.

The Alzheimer's angle

Friday's second announcement may matter even more over time. Pathos also entered a collaboration with Bristol Myers Squibb and Tempus AI to develop AI tools for drug discovery in Alzheimer's disease and other neurological disorders.

Under the deal, Tempus will build a de-identified, long-term dataset from hundreds of thousands of patients with neurological conditions, tracking how their health changes over the years. Pathos will license that data for $55 million over five years and aim Foundry at it to test ideas about disease biology and design tighter, more adaptive clinical trials.

In return, Bristol Myers gets three-year exclusive rights to use the platform in its neuroscience development programs, plus strategic access to Foundry across its wider research portfolio. Alzheimer's has been one of medicine's hardest battlegrounds, with a long history of costly trial failures, and BMS says it hopes AI insights will help it understand disease progression and find the patients most likely to benefit from new treatments.

Big pharma keeps shopping for AI

The deal fits a wider pattern of drugmakers teaming up with AI companies rather than building everything in-house, much like the AstraZeneca partnership with insitro. For Pathos, the structure is clever: the same round that revalues the company at $3 billion also locks its lead investor into a commercial relationship that could outlast the funding itself.

By Hamza Faisal